secwatch / observer
8-K filed March 22, 2023, 7:59 PM ET ticker CALC CIK 0001534133
M&A confidence high sentiment negative materiality 0.90

CalciMedica, Inc. (CALC): Nasdaq/NYSE listing notice — CalciMedica closes reverse merger with Graybug; Nasdaq delisting notice received for failing initial listing criteria

CalciMedica, Inc.

item 2.01item 3.01item 9.01item 3.02item 3.03item 5.01item 5.02item 5.03item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christy Shaffer

Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Departed

Eric Bjerkholt

Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Departed

Julie Eastland

Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Departed

Christina Ackermann

Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Departed

Dirk Sauer

Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
Appointed

Allan Shaw

Class III Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Allan Shaw 59 Class III Director
Appointed

Eric Bjerkholt

Class I Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Eric Bjerkholt was reappointed to the Company’s board of directors as a Class I director, effective as of the effective time of the Merger.
Appointed

A. Rachel Leheny

Chief Executive Officer and Class II Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
A. Rachel Leheny, Ph.D. 59 Chief Executive Officer and Class II Director
Appointed

Fred Middleton

Class I Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Fred Middleton 73 Class I Director
Appointed

Eric W. Roberts

Chief Business Officer and Class II Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Eric W. Roberts 59 Chief Business Officer and Class II Director
Departed (interim)

Robert S. Breuil

Chief Financial Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Successor
Daniel Geffken
Filed
March 22, 2023, 7:59 PM ET
each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.
Appointed

Sudarshan Hebbar

Chief Medical Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Sudarshan Hebbar, M.D. 58 Chief Medical Officer
Departed

Parisa Zamiri

Other Named Officer
CALC · CalciMedica, Inc.
Effective
2023-02-28
Filed
March 22, 2023, 7:59 PM ET
on February 28, 2023, the board of directors of Graybug terminated Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger.
Appointed

Michael J. Dunn

President and Chief Operating Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Michael J. Dunn, MBA 67 President and Chief Operating Officer
Departed

Frederic Guerard

President and Chief Executive Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Successor
A. Rachel Leheny
Filed
March 22, 2023, 7:59 PM ET
each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.
Appointed

Kenneth A. Stauderman

Chief Scientific Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Kenneth A. Stauderman, Ph.D. 70 Chief Scientific Officer
Appointed (interim)

Daniel Geffken

Interim Chief Financial Officer
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Daniel Geffken, MBA 66 Interim Chief Financial Officer
Appointed

Frederic Guerard

Class II Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Frederic Guerard, Pharm.D. 50 Class II Director
Appointed

Robert N. Wilson

Chair of the Board and Class III Director
CALC · CalciMedica, Inc.
Effective
2023-03-20
Filed
March 22, 2023, 7:59 PM ET
Robert N. Wilson 82 Chair of the Board and Class III Director

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CalciMedica, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5110(a), 5405(b)(2)(A), 5405(b)(2)(C)).

Exchange
nasdaq
Notice
delisting notice
Deficiency
stockholders equity
Rules
5110(a), 5405(b)(2)(A), 5405(b)(2)(C)
Exact text from the filing
March 21, 2023, the Company received written notice (the “Notice”) from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Staff has determined that the Company has not complied with the requirements of Nasdaq Listing Rule 5110(a) because the Company did not demonstrate compliance with all of the requirements for initial listing on Nasdaq concurrent with closing the merger transaction. Specifically, the Company did not meet the minimum stockholders’ equity requirement pursuant to Nasdaq Listing Rule 5405(b)(2)(A), the Mar
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Christy Shaffer resigned as Director at CalciMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Bjerkholt resigned as Director at CalciMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Eastland resigned as Director at CalciMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Christina Ackermann resigned as Director at CalciMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dirk Sauer resigned as Director at CalciMedica, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Shaw was appointed as Class III Director at CalciMedica, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
Allan Shaw 59 Class III Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Bjerkholt was appointed as Class I Director at CalciMedica, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
Eric Bjerkholt was reappointed to the Company’s board of directors as a Class I director, effective as of the effective time of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

A. Rachel Leheny was appointed as Chief Executive Officer and Class II Director at CalciMedica, Inc..

Action
appointed
Role
Chief Executive Officer and Class II Director
Exact text from the filing
A. Rachel Leheny, Ph.D. 59 Chief Executive Officer and Class II Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Middleton was appointed as Class I Director at CalciMedica, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
Fred Middleton 73 Class I Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Eric W. Roberts was appointed as Chief Business Officer and Class II Director at CalciMedica, Inc..

Action
appointed
Role
Chief Business Officer and Class II Director
Exact text from the filing
Eric W. Roberts 59 Chief Business Officer and Class II Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert S. Breuil was terminated as Chief Financial Officer at CalciMedica, Inc..

Action
terminated
Role
Chief Financial Officer
Exact text from the filing
each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sudarshan Hebbar was appointed as Chief Medical Officer at CalciMedica, Inc..

Action
appointed
Role
Chief Medical Officer
Exact text from the filing
Sudarshan Hebbar, M.D. 58 Chief Medical Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.7

Parisa Zamiri was terminated as other_named_officer at CalciMedica, Inc..

Action
terminated
Exact text from the filing
on February 28, 2023, the board of directors of Graybug terminated Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael J. Dunn was appointed as President and Chief Operating Officer at CalciMedica, Inc..

Action
appointed
Role
President and Chief Operating Officer
Exact text from the filing
Michael J. Dunn, MBA 67 President and Chief Operating Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frederic Guerard was terminated as President and Chief Executive Officer at CalciMedica, Inc..

Action
terminated
Role
President and Chief Executive Officer
Exact text from the filing
each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth A. Stauderman was appointed as Chief Scientific Officer at CalciMedica, Inc..

Action
appointed
Role
Chief Scientific Officer
Exact text from the filing
Kenneth A. Stauderman, Ph.D. 70 Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Geffken was appointed as Interim Chief Financial Officer at CalciMedica, Inc..

Action
appointed
Role
Interim Chief Financial Officer
Exact text from the filing
Daniel Geffken, MBA 66 Interim Chief Financial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frederic Guerard was appointed as Class II Director at CalciMedica, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Frederic Guerard, Pharm.D. 50 Class II Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert N. Wilson was appointed as Chair of the Board and Class III Director at CalciMedica, Inc..

Action
appointed
Role
Chair of the Board and Class III Director
Exact text from the filing
Robert N. Wilson 82 Chair of the Board and Class III Director
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CalciMedica, Inc.: Certificate of Amendment filed to change company name from Graybug Vision, Inc. to CalciMedica, Inc (effective 2023-03-20).

Change
charter amendment
Effective
2023-03-20
Exact text from the filing
Immediately prior to the consummation of the Merger, on March 20, 2023, Graybug filed the Certificate of Amendment changing its name from “Graybug Vision, Inc.” to “CalciMedica, Inc.”
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

CalciMedica, Inc. underwent a change of control involving CalciMedica, Inc. (closed 2023-03-20).

Action
change of control
Counterparty
CalciMedica, Inc.
Closing
2023-03-20
Exact text from the filing
On March 20, 2023, Graybug, Merger Sub and CalciMedica consummated the transactions contemplated by the Merger Agreement following the Special Meeting.
View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CalciMedica, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-076714
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.